Published on
Monday, November 5, 2012
Immigration isn't on the to-do
lists for American biopharma lobbyists, and it apparently isn't on the radar
screens of most industry leaders in the U.S. They may be surprised to learn
that Congress stands ready to discriminate against life scientists trained with
NIH dollars but born somewhere else.
BioCentury stands at the head
of the line when it comes to advocating the globalization of bioscience, with
the benefits it will provide everywhere in terms of public health, jobs and
national wealth. But that does not mean taking the U.S. for granted, especially
when politics has produced wrong-headed ideas that now threaten to explicitly
discriminate against talent that the biopharma industry needs to drive
innovation.